Fate Therapeutics (FATE) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
13 May, 2026Executive summary
Report covers the quarter ended March 31, 2026, for a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, with a pipeline including off-the-shelf, multiplexed-engineered T-cell and NK-cell product candidates and ongoing collaborations, notably with Ono Pharmaceutical.
Initiation of RECLAIM-LN Phase 2 trial for FT819 in lupus nephritis planned for H2 2026, with unique, less-intensive conditioning and on-demand product availability.
FT819 selected for FDA's CDRP program, enhancing regulatory engagement and potentially accelerating registration pathway.
Clinical data for FT819 show meaningful and durable responses in SLE, with improved safety and quality of life, including outpatient treatment feasibility.
Next-generation CAR T-cell programs FT839 and FT836 advancing, with FT839 IND submission planned and FT836 showing favorable safety in early trials.
Financial highlights
Collaboration revenue was $1.3 million, down from $1.6 million year-over-year, primarily from research and preclinical development services with Ono Pharmaceutical.
Research and development expenses decreased to $24.7 million from $29.1 million, and general and administrative expenses fell to $9.6 million from $13.8 million, mainly due to lower employee and stock-based compensation.
Total operating expenses for Q1 2026 were $34.3 million, down 20% year-over-year.
Net loss for Q1 2026 was $31.2 million, compared to $37.6 million in the prior year quarter.
Cash, cash equivalents, and short-term investments totaled $174.8 million as of March 31, 2026, expected to fund operations for at least the next twelve months and extend runway into 2028.
Outlook and guidance
Management expects continued significant operating losses as research, development, and manufacturing activities persist.
Sufficient funding is projected for at least the next twelve months, with runway extended into 2028, but additional capital will be required for long-term operations and product development.
Enrollment for RECLAIM-LN expected to complete within 15 months of trial initiation.
Further clinical updates anticipated at major scientific conferences in 2026.
Latest events from Fate Therapeutics
- FT819 advances off-the-shelf CAR T into lupus nephritis and broader autoimmune care.FATE
Jefferies Global Healthcare Conference - $100 million Leerink ATM adds financing flexibility but carries material dilution risk.FATE
Registration filing - RECLAIM-LN advanced as management’s grant-inclusive runway outlook extended to mid-2028.FATE
Q3 2026 - Scalable CAR T platform shows strong safety, efficacy, and promising phase II progress in lupus nephritis.FATE
12th Annual Cantor Fitzgerald Global Healthcare Conference - Net loss narrowed, cash runway into 2028, and pivotal CAR T-cell trials advanced.FATE
Q2 2026 - Early lupus trial data with flexible CAR T protocols expected by year-end, focusing on B-cell reset.FATE
Jefferies 2024 Global Healthcare Conference - FT819 and next-gen CAR T-cell therapies show strong clinical progress and financial stability.FATE
Corporate presentation - Key votes include director elections, auditor ratification, and incentive plan amendment.FATE
Proxy filing - Shareholders will vote on director elections, auditor ratification, say-on-pay, and equity plan expansion.FATE
Proxy filing